This Article Figures Only Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waseda, K. Search for Related Content PubMed Articles by Waseda, K.

Intravascular Ultrasound Results From the ENDEAVOR IV Trial

Randomized Comparison Between Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

Katsuhisa Waseda, MD, PhD^_*, Akiyoshi Miyazawa, MD^_*, Junya Ako, MD, PhD^_*, Takao Hasegawa, MD^_*, Ichizo Tsujino, MD, PhD^_*, Ryota Sakurai, MD, PhD^_*, Paul G. Yock, MD^_*, Yasuhiro Honda, MD^_*, David E. Kandzari, MD, Martin B. Leon, MD, Peter J. Fitzgerald, MD, PhD^_*,_* for the ENDEAVOR IV Trial Investigators

^_* Center for Cardiovascular Technology, Division of Cardiovascular Medicine, Stanford University, Stanford, California
Scripps Green Hospital, La Jolla, California
Columbia University, New York, New York

^_* Reprint requests and correspondence: Dr. Peter J. Fitzgerald, Cardiovascular Medicine, Stanford University, 300 Pasteur Drive, Room H3554, Stanford, California 94305 (Email: crci-cvmed{at}stanford.edu).

Objectives: The aim of this study was to compare the vessel response between zotarolimus-eluting stents (ZES) and paclitaxel-eluting stents (PES) using intravascular ultrasound.

Background: The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting, phosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared with using PES for the same treatment.

Methods: Data were obtained from patients with serial (baseline and 8-months follow-up) intravascular ultrasound analysis available (n = 198). Volumetric analysis was performed for vessel, lumen, plaque, stent, and neointima. Cross-sectional narrowing (given as percentage) was defined as neointimal area divided by stent area. Neointima-free frame ratio was calculated as the number of frames without intravascular ultrasound-detectable neointima divided by the total number of frames within the stent. Subsegment analysis was performed at every matched 1-mm subsegment throughout the stent.

Results: At follow-up, the ZES group showed significantly greater percentage of neointimal obstruction (16.6 ± 12.0% vs. 9.9 ± 8.9%, p < 0.01) and maximum cross-sectional narrowing (31.8 ± 16.1% vs. 25.2 ± 14.9%, p < 0.01) with smaller minimum lumen area than the PES group did. However, the incidence of maximum cross-sectional narrowing >50% was similar in the 2 groups. Neointima-free frame ratio was significantly lower in the ZES group. In overall analysis, whereas the PES group showed positive remodeling during follow-up (13.7 ± 4.2 mm³/mm to 14.3 ± 4.3 mm³/mm), the ZES group showed no significant difference (12.7 ± 3.6 mm³/mm to 12.9 ± 3.5 mm³/mm). In subsegment analysis, significant focal positive vessel remodeling was observed in 5% of ZES and 25% of PES cases (p < 0.05).

Conclusions: There were different global and focal vessel responses for ZES and PES. Both drug-eluting stents showed a similar incidence of lesions with severe narrowing despite ZES having a moderate increase in neointimal hyperplasia compared with neointimal hyperplasia in PES. There was a relatively lower neointima-free frame ratio in ZES, suggesting a greater extent of neointimal coverage. (The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions; NCT00217269)

Key Words: ultrasound • zotarolimus-eluting stent • coronary artery disease

Abbreviations and Acronyms   CSN = cross-sectional narrowing   DES = drug-eluting stent(s)   ISA = incomplete stent apposition   IVUS = intravascular ultrasound   PES = paclitaxel-eluting stent(s)   VI = volume index   ZES = zotarolimus-eluting stent(s)

This article has been cited by other articles:

				V. Esteban, N. Mendez-Barbero, L. Jesus Jimenez-Borreguero, M. Roque, L. Novensa, A. Belen Garcia-Redondo, M. Salaices, L. Vila, M. L. Arbones, M. R. Campanero, et al. Regulator of calcineurin 1 mediates pathological vascular wall remodeling J. Exp. Med., September 26, 2011; 208(10): 2125 - 2139. [Abstract] [Full Text] [PDF]

				K. Waseda, J. Ako, M. Yamasaki, T. Koizumi, R. Sakurai, Y. Hongo, B.-K. Koo, J. Ormiston, S. G. Worthley, R. J. Whitbourn, et al. Impact of Polymer Formulations on Neointimal Proliferation After Zotarolimus-Eluting Stent With Different Polymers: Insights From the RESOLUTE Trial Circ Cardiovasc Interv, June 1, 2011; 4(3): 248 - 255. [Abstract] [Full Text] [PDF]

				G. Guagliumi, V. Sirbu, H. Bezerra, G. Biondi-Zoccai, L. Fiocca, G. Musumeci, A. Matiashvili, N. Lortkipanidze, S. Tahara, O. Valsecchi, et al. Strut Coverage and Vessel Wall Response to Zotarolimus-Eluting and Bare-Metal Stents Implanted in Patients With ST-Segment Elevation Myocardial Infarction: The OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study J. Am. Coll. Cardiol. Intv., June 1, 2010; 3(6): 680 - 687. [Abstract] [Full Text] [PDF]

				D. Mukherjee and D. J. Moliterno Second-Generation Drug-Eluting Stents and the Continuous Need for Rapidly Available Real-World Data J. Am. Coll. Cardiol. Intv., December 1, 2009; 2(12): 1236 - 1239. [Full Text] [PDF]